Intervention

Tucatinib

ClinicalTrials.gov intervention label

Clinical trials32
Recruiting6
Common conditions25
Lead sponsors shown15

Clinical trials

32 shown
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21
RECRUITING
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)NCT06686394 · 2025-02-26
RECRUITING
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerNCT06439693 · 2024-08-08
RECRUITING
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyNCT06162559 · 2023-12-18
RECRUITING
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerNCT05748834 · 2023-07-24
RECRUITING
PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15
RECRUITING
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNCT07494448 · 2026-07-01
NOT_YET_RECRUITING
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.NCT06961331 · 2025-05-07
COMPLETED
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerNCT06239467 · 2024-02-26
ACTIVE_NOT_RECRUITING
Tucatinib+Trastuzumab+Eribulin in HER2+ MBCNCT05458674 · 2024-01-30
ACTIVE_NOT_RECRUITING
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNCT06067776 · 2024-01-01
NOT_YET_RECRUITING
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainNCT05892068 · 2023-05-09
ACTIVE_NOT_RECRUITING
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibNCT05323955 · 2023-03-23
ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerNCT05583110 · 2023-03-08
TERMINATED
Tucatinib Together With Pembrolizumab and TrastuzumabNCT04789096 · 2023-03-07
TERMINATED
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.NCT05230810 · 2022-08-25
ACTIVE_NOT_RECRUITING
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364 · 2022-06-29
ACTIVE_NOT_RECRUITING
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesNCT04512261 · 2022-06-01
WITHDRAWN
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerNCT05227131 · 2022-05-15
WITHDRAWN
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerNCT05319873 · 2022-04-07
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07
ACTIVE_NOT_RECRUITING
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerNCT05041842 · 2021-12-17
ACTIVE_NOT_RECRUITING
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.NCT04896320 · 2021-12-15
WITHDRAWN
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)NCT04721977 · 2021-04-08
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02
ACTIVE_NOT_RECRUITING
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerNCT04538742 · 2020-12-28
ACTIVE_NOT_RECRUITING
Tucatinib + Abemaciclib + Herceptin for HER2+ MBCNCT03846583 · 2020-06-28
WITHDRAWN
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDNCT03501979 · 2019-02-20
TERMINATED
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersNCT02892123 · 2016-09-30
COMPLETED
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerNCT02025192 · 2013-12-31
COMPLETED
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerNCT04220203
APPROVED_FOR_MARKETING
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerNCT03424473
NO_LONGER_AVAILABLE

Common conditions

Breast Cancer11HER2-positive Breast Cancer7Metastatic Breast Cancer5HER2-positive Metastatic Breast Cancer3Advanced Breast Cancer2Anatomic Stage II Breast Cancer AJCC v82Anatomic Stage III Breast Cancer AJCC v82Brain Metastases2Breast Neoplasms2Invasive Breast Carcinoma2Metastatic HER2+ Advanced Breast Cancer2Adenocarcinoma1Adenocarcinoma of Colon1Advanced Cancer1Advanced Solid Tumors1Anatomic Stage I Breast Cancer AJCC v81Anatomic Stage IIA Breast Cancer AJCC v81Anatomic Stage IIB Breast Cancer AJCC v81Anatomic Stage IIIA Breast Cancer AJCC v81Anatomic Stage IIIB Breast Cancer AJCC v81Anatomic Stage IIIC Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81Breast Cancer Female1Breast Cancer Metastatic1Breast Cancer Stage IV1

Trial status mix

ACTIVE_NOT_RECRUITING12
RECRUITING6
WITHDRAWN4
COMPLETED3
TERMINATED3
NOT_YET_RECRUITING2
APPROVED_FOR_MARKETING1
NO_LONGER_AVAILABLE1

Phase mix

PHASE220
PHASE115
PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.